Pathological Hyaluronan Matrices in Cystic Fibrosis Airways and Secretions.

Hyaluronan (HA) has been used in treatment of cystic fibrosis (CF) via a nebulizer and has demonstrated success in clinical outcomes. HA is an important glycosaminoglycan that is cross-linked by heavy chains (HCs) from inter-α-inhibitor during inflammation. HC cross-linked HA (HC-HA) becomes significantly more adhesive for leukocytes than non-cross-linked HA, which can enhance inflammation. Our studies tested the hypothesis that HC-HA is present in CF airways and that altered ratios of HC-HA to its degradation into relatively lower molecular weight HA contribute to the pathophysiology of chronic inflammation in CF. We evaluated the distribution, levels, and size of HC-HA within CF, healthy, and diseased control lung, bronchus, and sputum tissues by histological and biochemical approaches. HC-HA was significantly elevated in CF, with deposits around the pulmonary vasculature, airway submucosa, and in the stroma of the submucosal glands. The increased infiltration of leukocyte populations correlated with the distribution of HC-HA matrices in the airways. Elevated lung tissue HC-HA correlated with decreased HA levels in CF mucus and sputum compared with controls, suggesting that aberrant degradation and cross-linking of HA in lung tissue is a unique feature of CF. The accumulation and degradation of proinflammatory HC-HA in CF lung tissue suggests that aberrant HA catabolism and cross-linking may contribute to chronic inflammation in airway tissues and affect mucus viscosity in CF airways.

[1]  R. Dweik,et al.  The Rise and Fall of Hyaluronan in Respiratory Diseases , 2015, International journal of cell biology.

[2]  C. A. de la Motte,et al.  Analysis of the heavy-chain modification and TSG-6 activity in pathological hyaluronan matrices. , 2015, Methods in molecular biology.

[3]  E. Roeb,et al.  Identification of Neutrophil Activation Markers as Novel Surrogate Markers of CF Lung Disease , 2014, PloS one.

[4]  B. Assael,et al.  Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. , 2014, Journal of aerosol medicine and pulmonary drug delivery.

[5]  C. A. de la Motte,et al.  Hyaluronan, a Crucial Regulator of Inflammation , 2014, Front. Immunol..

[6]  R. Dweik,et al.  Modification of Hyaluronan by Heavy Chains of Inter-α-Inhibitor in Idiopathic Pulmonary Arterial Hypertension* , 2014, The Journal of Biological Chemistry.

[7]  V. Villella,et al.  Nebulized Hyaluronan Ameliorates lung inflammation in cystic fibrosis mice , 2013, Pediatric pulmonology.

[8]  A. Naselli,et al.  Inhaled hypertonic saline+hyaluronic acid in cystic fibrosis with asthma-like symptoms: a new therapeutic chance , 2013, BMJ Case Reports.

[9]  V. Hascall,et al.  Tumor Necrosis Factor-stimulated Gene-6 (TSG-6) Amplifies Hyaluronan Synthesis by Airway Smooth Muscle Cells* , 2012, The Journal of Biological Chemistry.

[10]  M. Collura,et al.  Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, double-blind, controlled study , 2012, Therapeutic advances in respiratory disease.

[11]  L. S. Cortina,et al.  [Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis]. , 2012, Medicina clinica.

[12]  L. Máiz Carro,et al.  [Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis]. , 2012, Medicina clinica.

[13]  S. Garantziotis,et al.  Hyaluronan Signaling during Ozone-Induced Lung Injury Requires TLR4, MyD88, and TIRAP , 2011, PloS one.

[14]  C. A. de la Motte,et al.  Agarose and polyacrylamide gel electrophoresis methods for molecular mass analysis of 5- to 500-kDa hyaluronan. , 2011, Analytical biochemistry.

[15]  C. A. de la Motte,et al.  Hyaluronan matrices in pathobiological processes , 2011, The FEBS journal.

[16]  N. McElvaney,et al.  The Involvement of Glycosaminoglycans in Airway Disease Associated with Cystic Fibrosis , 2011, TheScientificWorldJournal.

[17]  P. Noble,et al.  Hyaluronan as an immune regulator in human diseases. , 2011, Physiological reviews.

[18]  V. Raia,et al.  Hyaluronic acid improves “pleasantness” and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis , 2010, Advances in therapy.

[19]  U. Schumacher,et al.  Cystic Fibrosis Transmembrane Conductance Regulator Can Export Hyaluronan , 2010, Pathobiology.

[20]  T. Wight,et al.  Organization of Hyaluronan and Versican in the Extracellular Matrix of Human Fibroblasts Treated With the Viral Mimetic Poly I:C , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[21]  C. A. de la Motte,et al.  Primary Murine Airway Smooth Muscle Cells Exposed to Poly(I,C) or Tunicamycin Synthesize a Leukocyte-adhesive Hyaluronan Matrix* , 2009, Journal of Biological Chemistry.

[22]  M. J. Jedrzejas,et al.  The many ways to cleave hyaluronan. , 2007, Biotechnology advances.

[23]  A. Mantovani,et al.  PTX3 interacts with inter-alpha-trypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion. , 2007, The Journal of biological chemistry.

[24]  Marilyn S. Rugg,et al.  The molecular basis of inter-alpha-inhibitor heavy chain transfer on to hyaluronan. , 2007, Biochemical Society transactions.

[25]  Robert Stern,et al.  Hyaluronan fragments: an information-rich system. , 2006, European journal of cell biology.

[26]  R. Kannagi,et al.  SHAP Potentiates the CD44-mediated Leukocyte Adhesion to the Hyaluronan Substratum* , 2006, Journal of Biological Chemistry.

[27]  Victoria A. Higman,et al.  TSG-6: a pluripotent inflammatory mediator? , 2006, Biochemical Society transactions.

[28]  C. A. de la Motte,et al.  Copyright © American Society for Investigative Pathology Mononuclear Leukocytes Bind to Specific Hyaluronan Structures on Colon Mucosal Smooth Muscle Cells Treated with Polyinosinic Acid:Polycytidylic Acid Inter-�-Trypsin Inhibitor Is Crucial to Structure , 2022 .

[29]  R. Midura,et al.  Microanalysis of enzyme digests of hyaluronan and chondroitin/dermatan sulfate by fluorophore-assisted carbohydrate electrophoresis (FACE). , 2000, Glycobiology.

[30]  J. Baraniuk,et al.  Hyaluronan is exocytosed from serous, but not mucous cells, of human nasal and tracheobronchial submucosal glands. , 1996, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[31]  S. Kurono,et al.  Evidence for the Covalent Binding of SHAP, Heavy Chains of Inter-α-Trypsin Inhibitor, to Hyaluronan (*) , 1995, The Journal of Biological Chemistry.

[32]  L. Huang,et al.  A serum-derived hyaluronan-associated protein (SHAP) is the heavy chain of the inter alpha-trypsin inhibitor. , 1993, The Journal of biological chemistry.

[33]  H. Devaraj,et al.  Purification of mucin glycoproteins by density gradient centrifugation in cesium trifluoroacetate. , 1992, Analytical biochemistry.

[34]  T. Laurent.  Biochemistry of hyaluronan. , 1987, Acta oto-laryngologica. Supplementum.